{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:19:30Z","timestamp":1785910770853,"version":"3.56.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00520-024-08674-1","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T11:01:59Z","timestamp":1720522919000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Strategies for DPYD testing prior to fluoropyrimidine chemotherapy in the US"],"prefix":"10.1007","volume":"32","author":[{"given":"Tabea","family":"Tracksdorf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3667-2936","authenticated-orcid":false,"given":"D. Max","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skyler","family":"Pearse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3595-9321","authenticated-orcid":false,"given":"Emily J.","family":"Cicali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6609-6920","authenticated-orcid":false,"given":"Christina L.","family":"Aquilante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5720-1864","authenticated-orcid":false,"given":"Stuart A.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2489-3099","authenticated-orcid":false,"given":"Teresa T.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9845-3697","authenticated-orcid":false,"given":"Jai N.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2314-0164","authenticated-orcid":false,"given":"J. Kevin","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0501-1035","authenticated-orcid":false,"given":"Daniel L.","family":"Hertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"8674_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.15386\/mpr-1564","volume":"93","author":"A-L Deac","year":"2020","unstructured":"Deac A-L, Burz CC, Boc\u0219e HF et al (2020) A systematic review on the importance of genotyping and phenotyping in fluoropyrimidine treatment. Med Pharm Rep 93:223\u2013230. https:\/\/doi.org\/10.15386\/mpr-1564","journal-title":"Med Pharm Rep"},{"key":"8674_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2015.11.008","volume":"54","author":"CATC Lunenburg","year":"2016","unstructured":"Lunenburg CATC, Henricks LM, Guchelaar H-J et al (2016) Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: ready for prime time. Eur J Cancer 54:40\u201348. https:\/\/doi.org\/10.1016\/j.ejca.2015.11.008","journal-title":"Eur J Cancer"},{"key":"8674_CR3","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/onco.13967","volume":"26","author":"BB Sharma","year":"2021","unstructured":"Sharma BB, Rai K, Blunt H et al (2021) Pathogenic DPYD Variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis. Oncologist 26:1008\u20131016. https:\/\/doi.org\/10.1002\/onco.13967","journal-title":"Oncologist"},{"key":"8674_CR4","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41431-019-0540-0","volume":"28","author":"CATC Lunenburg","year":"2020","unstructured":"Lunenburg CATC, van der Wouden CH, Nijenhuis M et al (2020) Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene\u2013drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet 28:508\u2013517. https:\/\/doi.org\/10.1038\/s41431-019-0540-0","journal-title":"Eur J Hum Genet"},{"key":"8674_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM et al (2018) Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103:210\u2013216. https:\/\/doi.org\/10.1002\/cpt.911","journal-title":"Clin Pharmacol Ther"},{"key":"8674_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/clpt.2013.69","volume":"94","author":"SM Offer","year":"2013","unstructured":"Offer SM, Lee AM, Mattison LK et al (2013) A DPYD variant (Y186C) in individuals of African ancestry associated with reduced DPD enzyme activity. Clin Pharmacol Ther 94:158\u2013166. https:\/\/doi.org\/10.1038\/clpt.2013.69","journal-title":"Clin Pharmacol Ther"},{"key":"8674_CR7","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1200\/JCO.23.00038","volume":"41","author":"DL Hertz","year":"2023","unstructured":"Hertz DL (2023) Reply to H.S. Hochster. JCO 41:2120\u20132121. https:\/\/doi.org\/10.1200\/JCO.23.00038","journal-title":"JCO"},{"key":"8674_CR8","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (2018) Screening for dihydropyrimidine dehydrogenase deficiency to decrease the risk of severe toxicities related to fluoropyrimidines (5-fluorouracil or capecitabine) - INAHTA Brief. https:\/\/www.has-sante.fr\/jcms\/c_2891090\/en\/screening-for-dihydropyrimidine-dehydrogenase-deficiency-to-decrease-the-risk-of-severe-toxicities-related-to-fluoropyrimidines-5-fluorouracil-or-capecitabine-inahta-brief. Accessed 7 Mar 2024"},{"key":"8674_CR9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/cpt.2608","volume":"112","author":"M de With","year":"2022","unstructured":"de With M, Knikman J, de Man FM et al (2022) Dihydropyrimidine dehydrogenase phenotyping using pretreatment uracil: a note of caution based on a large prospective clinical study. Clin Pharmacol Ther 112:62\u201368. https:\/\/doi.org\/10.1002\/cpt.2608","journal-title":"Clin Pharmacol Ther"},{"key":"8674_CR10","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","volume":"19","author":"LM Henricks","year":"2018","unstructured":"Henricks LM, Lunenburg CATC, de Man FM et al (2018) DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 19:1459\u20131467. https:\/\/doi.org\/10.1016\/S1470-2045(18)30686-7","journal-title":"Lancet Oncol"},{"key":"8674_CR11","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1016\/j.clcc.2022.05.001","volume":"21","author":"GA Brooks","year":"2022","unstructured":"Brooks GA, Tapp S, Daly AT et al (2022) Cost-effectiveness of DPYD genotyping prior to fluoropyrimidine-based adjuvant chemotherapy for colon cancer. Clin Colorectal Cancer 21:e189\u2013e195. https:\/\/doi.org\/10.1016\/j.clcc.2022.05.001","journal-title":"Clin Colorectal Cancer"},{"key":"8674_CR12","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1093\/ajhp\/zxad117","volume":"80","author":"SA Morris","year":"2023","unstructured":"Morris SA, Moore DC, Musselwhite LW et al (2023) Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center. Am J Health Syst Pharm 80:1342\u20131349. https:\/\/doi.org\/10.1093\/ajhp\/zxad117","journal-title":"Am J Health Syst Pharm"},{"key":"8674_CR13","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1200\/OP.20.00553","volume":"16","author":"F Innocenti","year":"2020","unstructured":"Innocenti F, Mills SC, Sanoff H et al (2020) All you need to know about DPYD genetic testing for patients treated with fluorouracil and capecitabine: a practitioner-friendly guide. JCO Oncol Pract 16:793\u2013798. https:\/\/doi.org\/10.1200\/OP.20.00553","journal-title":"JCO Oncol Pract"},{"key":"8674_CR14","unstructured":"NHS England (2020) Clinical commissioning urgent policy statement: pharmacogenomic testing for DPYD polymorphisms with fluoropyrimidine therapies. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2020\/11\/1869-dpyd-policy-statement.pdf. Accessed 2 Mar 2024"},{"key":"8674_CR15","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1159\/000510258","volume":"43","author":"B W\u00f6rmann","year":"2020","unstructured":"W\u00f6rmann B, Bokemeyer C, Burmeister T et al (2020) Dihydropyrimidine dehydrogenase testing prior to treatment with 5-fluorouracil, capecitabine, and tegafur: a consensus paper. Oncol Res Treat 43:628\u2013636. https:\/\/doi.org\/10.1159\/000510258","journal-title":"Oncol Res Treat"},{"key":"8674_CR16","doi-asserted-by":"publisher","unstructured":"de With M, Sadlon A, Cecchin E et al (2023) Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe. ESMO Open 8(2):101197. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101197","DOI":"10.1016\/j.esmoop.2023.101197"},{"key":"8674_CR17","unstructured":"European Medicines Agency (2020) New testing and treatment recommendations for fluorouracil, capecitabine, tegafur and flucytosine. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/fluorouracil-fluorouracil-related-substances-article-31-referral-new-testing-treatment_en.pdf. Accessed 2 Mar 2024"},{"key":"8674_CR18","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3390\/jpm13040638","volume":"13","author":"AL Halbisen","year":"2023","unstructured":"Halbisen AL, Lu CY (2023) Trends in availability of genetic tests in the United States, 2012\u20132022. J Pers Med 13:638. https:\/\/doi.org\/10.3390\/jpm13040638","journal-title":"J Pers Med"},{"key":"8674_CR19","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/s41436-020-0788-3","volume":"22","author":"HD Anderson","year":"2020","unstructured":"Anderson HD, Crooks KR, Kao DP, Aquilante CL (2020) The landscape of pharmacogenetic testing in a US managed care population. Genet Med 22:1247\u20131253. https:\/\/doi.org\/10.1038\/s41436-020-0788-3","journal-title":"Genet Med"},{"key":"8674_CR20","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/cpt.1006","volume":"104","author":"PE Empey","year":"2018","unstructured":"Empey PE, Stevenson JM, Tuteja S et al (2018) Multi-site investigation of strategies for the implementation of CYP2C19 genotype-guided antiplatelet therapy. Clin Pharmacol Ther 104:664\u2013674. https:\/\/doi.org\/10.1002\/cpt.1006","journal-title":"Clin Pharmacol Ther"},{"key":"8674_CR21","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1038\/s41436-019-0484-3","volume":"21","author":"LH Cavallari","year":"2019","unstructured":"Cavallari LH, Driest SLV, Prows CA et al (2019) Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. Genet Med 21:2255\u20132263. https:\/\/doi.org\/10.1038\/s41436-019-0484-3","journal-title":"Genet Med"},{"key":"8674_CR22","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/phar.2463","volume":"40","author":"LA Varughese","year":"2020","unstructured":"Varughese LA, Lau-Min KS, Cambareri C et al (2020) DPYD and UGT1A1 pharmacogenetic testing in patients with gastrointestinal malignancies: an overview of the evidence and considerations for clinical implementation. Pharmacotherapy 40:1108\u20131129. https:\/\/doi.org\/10.1002\/phar.2463","journal-title":"Pharmacotherapy"},{"key":"8674_CR23","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/cpt.2978","volume":"114","author":"DL Hertz","year":"2023","unstructured":"Hertz DL, Smith DM, Scott SA et al (2023) Response to the FDA decision regarding DPYD testing prior to fluoropyrimidine chemotherapy. Clin Pharmacol Ther 114:768\u2013779. https:\/\/doi.org\/10.1002\/cpt.2978","journal-title":"Clin Pharmacol Ther"},{"key":"8674_CR24","unstructured":"Benson et al. (2024) Colon cancer, version 1.2024, NCCN clinical practice guidelines in oncology. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf. Accessed 2 Mar 2024"},{"key":"8674_CR25","doi-asserted-by":"publisher","first-page":"e958","DOI":"10.1200\/OP.21.00874","volume":"18","author":"K Koo","year":"2022","unstructured":"Koo K, Pasternak AL, Henry NL et al (2022) Survey of US medical oncologists\u2019 practices and beliefs regarding DPYD testing before fluoropyrimidine chemotherapy. JCO Oncol Pract 18:e958\u2013e965. https:\/\/doi.org\/10.1200\/OP.21.00874","journal-title":"JCO Oncol Pract"},{"key":"8674_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12885-022-09171-6","volume":"22","author":"KS Lau-Min","year":"2022","unstructured":"Lau-Min KS, Varughese LA, Nelson MN et al (2022) Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation. BMC Cancer 22:47. https:\/\/doi.org\/10.1186\/s12885-022-09171-6","journal-title":"BMC Cancer"},{"key":"8674_CR27","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1200\/JCO.22.02364","volume":"41","author":"SD Baker","year":"2023","unstructured":"Baker SD, Bates SE, Brooks GA et al (2023) DPYD testing: time to put patient safety first. JCO 41:2701\u20132705. https:\/\/doi.org\/10.1200\/JCO.22.02364","journal-title":"JCO"},{"key":"8674_CR28","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1200\/JCO.22.00037","volume":"40","author":"DL Hertz","year":"2022","unstructured":"Hertz DL (2022) Assessment of the clinical utility of pretreatment DPYD testing for patients receiving fluoropyrimidine chemotherapy. JCO 40:3882\u20133892. https:\/\/doi.org\/10.1200\/JCO.22.00037","journal-title":"JCO"},{"key":"8674_CR29","doi-asserted-by":"publisher","unstructured":"Knikman JE, Wilting TA, Lopez-Yurda M, et al (2023) Survival of patients with cancer with DPYD variant alleles and dose-individualized fluoropyrimidine therapy\u2014a matched-pair analysis. J Clin Oncol 41(35):5411\u20135421. https:\/\/doi.org\/10.1200\/JCO.22.02780","DOI":"10.1200\/JCO.22.02780"},{"key":"8674_CR30","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1200\/OP.2023.19.11_suppl.396","volume":"19","author":"G Rompelman","year":"2023","unstructured":"Rompelman G, Espiritu J, Chen A et al (2023) Implementing a high-reliability, system-wide program for pre-emptive DPD deficiency testing for patients planned for a systemic fluoropyrimidine. JCO Oncol Pract 19:396\u2013396. https:\/\/doi.org\/10.1200\/OP.2023.19.11_suppl.396","journal-title":"JCO Oncol Pract"},{"key":"8674_CR31","doi-asserted-by":"publisher","first-page":"e13704","DOI":"10.1111\/cts.13704","volume":"17","author":"M Muldoon","year":"2024","unstructured":"Muldoon M, Beck M, Sebree N et al (2024) Real-world implementation of DPYD and UGT1A1 pharmacogenetic testing in a community-based cancer center. Clin Transl Sci 17:e13704. https:\/\/doi.org\/10.1111\/cts.13704","journal-title":"Clin Transl Sci"},{"key":"8674_CR32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","volume":"34","author":"MJ Deenen","year":"2016","unstructured":"Deenen MJ, Meulendijks D, Cats A et al (2016) Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. JCO 34:227\u2013234. https:\/\/doi.org\/10.1200\/JCO.2015.63.1325","journal-title":"JCO"},{"key":"8674_CR33","doi-asserted-by":"publisher","first-page":"1249003","DOI":"10.3389\/fgene.2023.1249003","volume":"14","author":"M Norris","year":"2023","unstructured":"Norris M, Dalton R, Alam B et al (2023) Lessons from clinical implementation of a preemptive pharmacogenetic panel as part of a testing pilot program with an employer-sponsored medical plan. Front Genet 14:1249003. https:\/\/doi.org\/10.3389\/fgene.2023.1249003","journal-title":"Front Genet"},{"key":"8674_CR34","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1188\/18.ONF.575-580","volume":"45","author":"C Dodson","year":"2018","unstructured":"Dodson C (2018) Oncology nurses\u2019 knowledge of pharmacogenomics before and after implementation of an education module. Oncol Nurs Forum 45:575\u2013580. https:\/\/doi.org\/10.1188\/18.ONF.575-580","journal-title":"Oncol Nurs Forum"},{"key":"8674_CR35","unstructured":"OneOme\u00ae The OneOme RightMed\u00ae Test. https:\/\/oneome.com\/rightmed-test\/. Accessed 15 Feb 2024"},{"key":"8674_CR36","unstructured":"RPRD diagnostics RPRD pharmacogenomics testing services. In: RPRDx. https:\/\/www.rprdx.com\/testing\/overview\/. Accessed 15 Feb 2024"},{"key":"8674_CR37","doi-asserted-by":"publisher","first-page":"712602","DOI":"10.3389\/fgene.2021.712602","volume":"12","author":"P Mroz","year":"2021","unstructured":"Mroz P, Michel S, Allen JD et al (2021) Development and implementation of in-house pharmacogenomic testing program at a major academic health system. Front Genet 12:712602. https:\/\/doi.org\/10.3389\/fgene.2021.712602","journal-title":"Front Genet"},{"key":"8674_CR38","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1158\/0008-5472.CAN-13-2482","volume":"74","author":"SM Offer","year":"2014","unstructured":"Offer SM, Fossum CC, Wegner NJ et al (2014) Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res 74:2545\u20132554. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2482","journal-title":"Cancer Res"},{"key":"8674_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41397-023-00322-x","volume":"24","author":"R Larrue","year":"2024","unstructured":"Larrue R, Fellah S, Hennart B et al (2024) Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity. Pharmacogenomics J 24:1. https:\/\/doi.org\/10.1038\/s41397-023-00322-x","journal-title":"Pharmacogenomics J"},{"key":"8674_CR40","doi-asserted-by":"publisher","unstructured":"Shriver SP, Adams D, McKelvey BA et al (2024) Overcoming barriers to discovery and implementation of equitable pharmacogenomic testing in oncology. J Clin Oncol JCO2301748. https:\/\/doi.org\/10.1200\/JCO.23.01748","DOI":"10.1200\/JCO.23.01748"},{"key":"8674_CR41","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0140-6736(22)01841-4","volume":"401","author":"JJ Swen","year":"2023","unstructured":"Swen JJ, van der Wouden CH, Manson LE et al (2023) A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. The Lancet 401:347\u2013356. https:\/\/doi.org\/10.1016\/S0140-6736(22)01841-4","journal-title":"The Lancet"},{"key":"8674_CR42","doi-asserted-by":"publisher","first-page":"1179364","DOI":"10.3389\/fphar.2023.1179364","volume":"14","author":"LK Lemke","year":"2023","unstructured":"Lemke LK, Alam B, Williams R et al (2023) Reimbursement of pharmacogenetic tests at a tertiary academic medical center in the United States. Front Pharmacol 14:1179364. https:\/\/doi.org\/10.3389\/fphar.2023.1179364","journal-title":"Front Pharmacol"},{"key":"8674_CR43","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41436-021-01117-w","volume":"23","author":"PE Empey","year":"2021","unstructured":"Empey PE, Pratt VM, Hoffman JM et al (2021) Expanding evidence leads to new pharmacogenomics payer coverage. Genet Med 23:830\u2013832. https:\/\/doi.org\/10.1038\/s41436-021-01117-w","journal-title":"Genet Med"},{"key":"8674_CR44","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/FPC.0000000000000507","volume":"33","author":"SA Morris","year":"2023","unstructured":"Morris SA, Grace Nguyen D, Lopes KE et al (2023) Assessing real-world clinical impact of an in-house dihydropyrimidine dehydrogenase (DPYD) genotyping test on fluoropyrimidine dosing and toxicity at a multisite cancer hospital. Pharmacogenet Genomics 33:204\u2013205. https:\/\/doi.org\/10.1097\/FPC.0000000000000507","journal-title":"Pharmacogenet Genomics"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08674-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08674-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08674-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T05:04:03Z","timestamp":1723611843000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08674-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["8674"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08674-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"2 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This survey was determined to be exempt human subjects research by the University of Michigan IRBMed (HUM00214220).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Survey participants supplied implied informed consent by participating in the survey.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"D.L.H. is an unpaid medical advisory board member for Advocates for Universal DPD\/DPYD Testing (AUDT), a non-profit patient advocacy organization that advocates for expansion of DPYD testing in the USA.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"497"}}